HanBio Therapeutics
Latest round
- Series A
Last raised
- Jan 2022
Total raised
- $40M
Investors
- 4
About HanBio Therapeutics
Based in Shanghai, China, and established in 2021, HanBio Therapeutics is a biotechnology company that focuses on R&D new drugs for treating tumors., Ltd that focuses on R&D, production, and sales of antibody drugs, and listed on Shanghai Stock Exchange under the number of 688336. The company's CEO is Dr. Zhenping Zhu, who has more than 28 years of R&D experience in pharmaceutical company, including 3SBio Group, Kadmon Holdings, ImClone Systems. Also, Dr. Zhenping Zhu has applied for more than 150 patents, and has published more than 200 peer-reviewed scientific papers in international journals. The company's product pipelines include three bispecific antibodies in the IND and pre-IND stages, and early-stage antibodies and other biologics products. Those new drugs take the technology of therapeutic targets. The company plans to perform preclinical research and clinical trials of multiple antibody and bispecific antibody products, and to introduce talents, and to establish company management system.
Who invested in HanBio Therapeutics
4 investors across 1 round
See all investors in HanBio Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 28, 2022
Amount
$40M
Investors
Questions about HanBio Therapeutics
Who invested in HanBio Therapeutics?
HanBio Therapeutics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HanBio Therapeutics raised?
HanBio Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did HanBio Therapeutics last raise money?
HanBio Therapeutics's most recent round on record is a Series A, in Jan 2022.
What does HanBio Therapeutics do?
Based in Shanghai, China, and established in 2021, HanBio Therapeutics is a biotechnology company that focuses on R&D new drugs for treating tumors.
Where is HanBio Therapeutics headquartered?
HanBio Therapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like HanBio Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at HanBio Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like HanBio Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.